Our services are tailored to accommodate clinical trials globally involving small patient numbers and to deal with the particular medical, scientific, clinical and commercial challenges within the rare disease domain.
The traditional global CRO model is tailored to manage large numbers of patients. The business and operational model of global organisations relies on substantial infrastructure to support these activities. A big part of this infrastructure consists of local subsidiaries that have historically been set up wherever clinical trials take place.
orphan reach employs a strategic partnering model. Whereas subsidiaries can offer benefits such as tax savings and corporate control, there are clear advantages when using an alternative delivery model in direct comparison:
– A highly dynamic and operationally proven model currently comprising of 15+ local and regional CRO partner organisations is fully scalable depending on where the patients and local expertise are needed
– Global access to local resources in excess of 100 countries as individually needed
– Reduced overhead costs
– Adaptive up- and down-scaling of resources without the typical change order costs
– Unrivaled motivation “on the ground” employing extremely knowledgeable local study personnel working in a non-corporate environment and driven by passion, not politics
– Operational hubs in Europe, US and Asia Pacific form the operational backbone and drive project delivery
In the past 12 years we have performed many international clinical trials and particularly in trials with small patient numbers Sponsors have learned to appreciate the difference it has made to their projects. To date our experience has been gained in more than 80 different rare disease trials.